This patent seems to cover the preservation of a kidney, despite its title. It may be that preservation is achieved through endogenous stem cell differentiation of kidney epithelium. The patent has one claim covering a method of preserving a kidney by contacting the kidney with a ligand for gp130 receptor (ie LIF, a cardiotrophin, a ciliary neuronotrophic factor...
This patent teaches how to induce formation of new kidney cells in vivo through the administration of ligands of gp130 such as LIF. This is one of the few patents that covers administration of therapies systemically that induce generation of new cells by stimulation of endogenous stem cells. This patent is in line with the approach of Transition Therapeutics...
This patent covers several amino acid and nucleotide sequences which are useful for modificatin of cellular differentiation and expansion. The claims refer to several sequence IDs, whereas the specification describes what appears to be numerous disjointed compositions of matter, uses, and formulations. For example, the patent specification talks about cadherins, then IL-17, then...
This patent covers methods of dedifferentiating cells, and redifferentiating them in order to produce islet-like cells for the treatment of diabetes.
This invention teaches how to generate neurons from skin. Essentially, the inventors found that through the process of isolating epidermal stem cells (basal cells), transfected said basal cells with genes encoding neurogenic transcription factors, suppressing transcription factors that maintain a differentiated phenotype (by for example antisense), and then culturing the cells with exogenous...
This invention is similar to patent 7041507, which was filed by the same inventors. The current invention teaches generation of neuronal-like cells through the transdifferentiation of epidermal basal cells. The invention has 3 independent claims covering, "An in vitro method of transdifferentiating an epidermal basal cell ", "A kit for transdifferentiating, in vitro, an epidermal...
This patent teaches how to induce "trandifferentiation" of epidermal cells into neurons. The neurons are useful for treatment of neurodegenerative diseases.
Gene therapy is limited by ability to transfect quiescent cells. Since the very primitive hematopoietic stem cells reside in a quiescent state, it is difficult to transfect them. This patent demonstrates transfection of early hematopoietic stem cells using an adeno-associated vector. The patent has one independent claim that covers:
A method for stably transferring
This patent provides frequencies of light that effect extracellular and cellular components. This patent is useful for regulation of stem cells after implantation into a host through non-pharmacological means.
Mesenchymal stem cells can be used as "universal donors" since they do not elicit rejection in certain situations. This patent teaches methods of differentiating mesenchymal stem cells into cartilage through growth on alginate layers.